Takeda Pharmaceutical Company Limited (Takeda) operates as a patient-focused, values-based, research and development (R&D)-driven global biopharmaceutical company with a diverse portfolio, engaged primarily in the research, development, production an…
Analysis
Bargain bin
Takeda Pharmaceutical Company Limited falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.
The price is attractive. You pay 10.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -3% yearly growth; analysts expect 13%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value. Analysts lean positive.
What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 20237
58
2023202420252026
All-time high
58
Jun 2026
All-time low
1
Aug 2024
Average rank
23
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
52
72
64
76
Price/Earnings
16
26
30
71
Price/Book
80
83
73
87
Dividend Yield
99
98
94
98
Value (overall)
75
86
80
75
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.